- Download this article, and see why you should subscribe today.
Abstract
- In patients with myocardial infarction who are not eligible for angioplasty, adding clopidogrel to aspirin reduces the overall 15-day mortality
rate, but the subsequent outcome is
not known.
- Previously approved in
combination with aspirin
for the treatment
of acute coronary syndromes
without ST depression, clopidogrel (Plavix°, Sanofi
Pharma, Bristol-Myers Squibb), is now
also approved for myocardial infarction
with ST elevation.
- In practice, in myocardial infarction
not treated with coronary angioplasty,
the addition of clopidogrel to aspirin
seems to benefit some patients (about 1
in 200). This combination may therefore
be used in the short term (4 weeks).
However, no evidence is available
beyond 4 weeks indicating a better risk-benefit
balance for aspirin plus clopidogrel
as compared to aspirin alone.
- The COMMIT study, designed to compare a
combination of clopidogrel and aspirin with aspirin alone in patients with ST elevation myocardial infarction , mobilised tens of thousands of people.
- What a shame! All this trial showed is
that, compared with aspirin alone, the
clopidogrel-aspirin combination significantly
reduces overall mortality… during
the next 15 days. What a shame that the investigators
did not evaluate effects on overall
mortality for at least a few months
after the myocardial infarction. So much
time, energy and money invested, so little
information in return.
©Prescrire August 2007
Source: Prescrire International 2007; 16 (90): 146.
- Download this article, and see why you should subscribe today.
- More articles in Prescrire's "Spotlight"...